Tuebingen

• A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham … Recruiting
  2023-504655-27-00 5 2024-12-23 Primary Indeterminate Lesions or Small Choroidal Melanoma
• A study comparing niraparib with temozolomide in adult participants with newly-diagnosed, MGMT unmethylated glioblastoma Recruiting
  2024-513077-48-00 5 2024-12-19 O6-methylguanine methyltransferase (MGMT) unmethylated glioblastoma
• Selective Treatment of Oral Povorcitinib in Prurigo Nodularis Study 1 (STOP-PN1) Recruiting
  2024-511879-16-00 5 2024-12-12 Prurigo Nodularis
• Concentration of ofatumumab in the breast milk of lactating women with relapsing forms of multiple sclerosis Recruiting
  2023-505283-11-00 6 2024-12-10 Relapsing forms of Multiple Sclerosis (RMS)
• A phase 3 multi-center trial to evaluate the efficacy and safety of tralokinumab in combination with topical corticosteroids in children (ag … Recruiting
  2023-503630-44-00 10 2024-11-20 Treatment of moderate-to-severe Atopic dermatitis
• A RANDOMIZED, OPEN-LABEL PHASE 3 STUDY IN PATIENTS WITH PREVIOUSLY TREATED UNRESECTABLE OR METASTATIC NRAS MUTANT CUTANEOUS MELANOMA COMPARI … Recruiting
  2024-511404-17-00 5 2024-10-07 Unresectable or metastatic NRAS mutant cutaneous melanoma
• A Trial Investigating Lu AG22515 in Adult Participants With Moderate-to-Severe Thyroid Eye Disease Recruiting
  2023-508693-29-00 3 2024-09-19 Active, moderate-to-severe TED
• AZD5305 vs Placebo in Men with Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents. Recruiting
  2023-504214-30-00 5 2024-06-27 Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
• BEAMION Lung-2: A study to test whether zongertinib (BI 1810631) helps people with advanced non-small cell lung cancer with HER2 mutations c … Recruiting
  2023-504308-27-00 5 2024-06-06 non-squamous non-small cell lung cancer
• A randomized phase III trial assessing iberdomide versus iberdomide plus isatuximab maintenance therapy post autologous hematopoietic stem-c … Recruiting
  2023-507402-13-00 5 2024-04-03 Multiple myeloma
• Multicenter phase 1b/II trial testing neoadjuvant intradermal Ipilimumab and Nivolumab in high risk stage II melanoma –MARIANE Recruiting
  2023-505945-19-00 4 2024-03-08 stage II melanoma
• A Phase 3, Open-Label, Uncontrolled Study to Evaluate the Activity, Safety, Pharmacokinetics and Pharmacodynamics of Roxadustat for the Trea … Recruiting
  2022-501980-42-00 5 2023-12-21 Anemia associated with Chronic Kidney Disease
• Prospective phase I/II trial of an individualized peptide vaccine in pediatric and AYA patients with metastasized fusion-driven sarcomas fol … Recruiting
  2024-511337-35-00 4 2023-11-16 The trial will include patients with so called "fusion-driven", metast
• A randomized study of XEN1101 versus placebo in Primary Generalised Tonic Clonic Seizures (X-ACKT) Recruiting
  2022-502286-16-00 5 2023-10-27 Primary Generalized Tonic-Clonic Seizures
• A phase 2, multicenter, double-blind, two-arm study of subcutaneous RO7790121 for the treatment of subjects with moderate to severe active c … Recruiting
  2023-504265-23-00 4 2023-10-23 Crohn's disease
• A Ph2 Superiority Study with InO Monotherapy vs ALLR3 for Induction Treatment of Childhood HR ALL Recruiting
  2023-509810-13-00 4 2023-05-13 Acute Lymphoblastic Leukemia (ALL)
• A randomized, open-label, phase II trial comparing neoadjuvant endocrine therapy in combination with trastuzumab, pertuzumab +/- the PI3K in … Recruiting
  2022-501152-28-00 4 2022-12-21 Breast Cancer
• Treatment of infants under one year with acute lymphoblastic leukemia according to the Interfant-21 protocol Recruiting
  2022-502503-30-00 5 2022-12-15 Acute lymphoblastic leukemia
• Evaluation of Niraparib alone compared to the combination of Niraparib and Bevacizumab in patients receiving chemotherapy for newly diagnose … Recruiting
  2024-516066-11-00 5 2022-08-31 Patients with newly diagnosed, histologically confirmed, primary advan
• A PROSPECTIVE, OPEN-LABEL, MULTICENTER, RANDOMIZED, PHASE 3 TRIAL OF ACALABRUTINIB, OBINUTUZUMAB AND VENETOCLAX (GAVE) COMPARED TO OBINUTUZU … Recruiting
  2023-506414-46-00 5 2022-04-22 High risk patients defined as having at least one of the following ris
• Efficacy and Safety of KAI-9531 in Participants Living With Obesity or Overweight and Diabetes Recruiting
  2025-523510-87-00 5 2026-06-25 Obesity
• A clinical trial to learn more about the effects of GIA632 in people with the most common type of vitiligo Recruiting
  2025-522301-37-00 4 2026-06-24 Nonsegmental vitiligo
• A Phase III, randomized, placebo-controlled, parallel group, double-blind study to evaluate the efficacy and safety of NIO752 in participant … Recruiting
  2025-523481-24-00 5 2026-06-24 Participants with Progressive Supranuclear Palsy Richardson Syndrome (
• Efficacy and Safety of KAI-9531 in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes Recruiting
  2025-523486-17-00 5 2026-06-16 Obesity

Showing 73–96 of 600 trials